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Abstract
Background: The clinical efficacy of effect-site targeted patient-maintained propofol sedation (PMPS) compared to
anaesthetist-controlled propofol sedation (ACPS) for patients undergoing awake joint replacement surgery is
currently unknown. There is no commercially available medical device capable of delivering PMPS so we have
designed and built such a device. We plan a clinical trial to compare PMPS to ACPS and to collect data relating to
the safety of our prototype device in delivering sedation.
Methods: The trial is an open-label, randomised, controlled superiority trial recruiting adults who are undergoing
elective primary lower-limb arthroplasty with sedation by propofol infusion by effect-site targeting into two
equal-sized parallel arms: PMPS and ACPS. The primary research objective is to compare the body-weight-normalised
rate of propofol consumption when sedation for surgery on adults undergoing elective primary lower-limb arthroplasty
under spinal anaesthesia is patient-maintained versus when it is anaesthetist-controlled. The study primary null
hypothesis is that there is no difference in the rate of propofol consumption when sedation is patient-maintained
versus anaesthetist-controlled.
Discussion: This is the first trial to test the superiority of effect-site-targeted patient-maintained propofol sedation
versus anaesthetist-controlled propofol sedation in terms of total propofol consumption during the sedation period.
The results of this trial will help inform clinicians and device manufacturers of the clinical efficacy and safety of
patient-maintained propofol sedation applied to a common operative setting.
Trial registration: International Standard Randomised Controlled Trial Number Registry, ISRCTN29129799. Prospectively
registered on 12 June 2018.
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Background
The most commonly performed lower limb surgical
arthroplasty procedures in the UK are primary hip re-
placement and primary knee replacement; respectively,
93,234 and 102,519 replacements were performed in
2016 (excluding Scotland) [1]. Regional anaesthesia, con-
sisting of a spinal anaesthetic with or without peripheral
nerve blockade, provides excellent operating conditions
and post-operative analgesia, reduces the risk of venous
thromboembolism, reduces transfusion requirements in
the peri-operative period and avoids some of the risks
associated with general anaesthesia [2].
Some patients are willing to experience surgery awake,
but a significant proportion of patients are fearful of this
experience pre-operatively and experience varying de-
grees of anxiety before and during the operation [3, 4].
Anaesthetists commonly supplement spinal anaesthesia
with sedation medication delivered intravenously for
lower limb arthroplasty in anxious patients. The aim of
sedation is to reduce anxiety and promote psychological
comfort, while minimising the physiological side effects
induced by deeper planes of sedation.
Sedation for lower limb arthroplasty is often provided
by the supervising anaesthetist using propofol by
intravenous computer-assisted target-controlled infusion
(anaesthetist-controlled propofol sedation (ACPS)) [5]. A
target-controlled infusion (TCI) device delivers a variable
rate of propofol in order to obtain and maintain a specified
effect-site (i.e. brain) drug concentration, until such time as
a new concentration is set by the supervising anaesthetist.
Their use is standard anaesthesia practice in the UK.
There is, however, an unpredictable individual dose re-
sponse to drugs inducing sedation, even using modern
ACPS with TCI systems. Furthermore, anaesthetists have
been shown to be poor judges of the pre-operative anxiety
states of individual patients [6]. For a variety of reasons, in-
cluding anxiety itself, patients do not always have precon-
ceived expectations about how sedated they wish to be for
surgery and these expectations are not always clearly com-
municated to (or understood by) the treating anaesthetist.
For these reasons it is difficult for anaesthetists to
sedate each individual to their preferred level using
ACPS. Under-sedation results in an anxious patient be-
cause their anxiolytic requirements are unmet during
surgery. Over-sedation results in a patient receiving an
unnecessarily deep level of sedation and heightened
exposure to the associated physiological harms even
though the patient would have willingly experienced sur-
gery at a lighter plane of sedation.
Patient-maintained propofol sedation (PMPS) involves
the use of a TCI system delivering propofol where the
effect-site concentration is influenced by the patient
using a handheld trigger. Allowing patients to influence
the depth of their sedation with a propofol TCI system
has already been described in small case series in healthy
volunteers [7] and in general [8], dental [9] and ambula-
tory outpatient surgery [10]. There are only three rando-
mised controlled trials of PMPS and none of these use
the Schnider effect-site-targeted propofol TCI model [5]
to compare PMPS against ACPS [11–13]. Our aim is to
assess the clinical efficacy of PMPS compared to ACPS.
There is no commercially available device to perform
PMPS, previous studies having relied on prototype de-
vices. We have therefore designed and built a device
capable of delivering PMPS for use in this clinical trial.
Methods/design
A standard protocol items: recommendation for inter-
ventional trials (SPIRIT) checklist detailing the items
addressed in this clinical trial protocol is provided as
Additional file 1.
Study objectives
The primary research objective is to compare the
body-weight-normalised rate of propofol consumption
when sedation for surgery on adults undergoing elective
primary lower-limb arthroplasty under spinal anaesthesia
(effect-site-targeted with propofol) is patient-maintained
versus when it is anaesthetist-controlled. The primary
outcome will be expressed as milligrams propofol per
kilogram actual body weight per hour of the sedation
period. The sedation period is defined as the time from
commencement of the allocated sedation regimen by the
supervising clinical anaesthetist (which will be after
spinal blockade is confirmed by clinical dermatomal test-
ing) until the sedation regimen is discontinued at the
end of surgery (which will be at the application by the
operating surgeon of clips to skin).
The study primary null hypothesis is that there is no dif-
ference in the rate of propofol consumption when sedation
it is patient-maintained versus anaesthetist-controlled. The
primary alternative hypothesis is that a patient-maintained
propofol sedation regimen will result in a minimum 29%
reduction in the rate at which propofol is consumed
over the course of the sedation period compared to
anaesthetist-controlled propofol sedation.
The secondary research objectives are:
 To establish whether patients are less deeply sedated
intra-operatively during patient-maintained sedation
compared to anaesthetist-controlled sedation.
 To assess whether patients undergoing PMPS have
equal reductions in peri-operative anxiety compared
to patients undergoing ACPS.
 To observe whether patients undergoing PMPS
have comparable post-operative satisfaction with
their sedation experience compared to patients
undergoing ACPS.
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 To explore whether patients who have undergone
PMPS are fit for discharge from the post-anaesthetic
care unit (PACU) sooner than patients who have
undergone ACPS.
 To determine if patients undergoing PMPS have
calculated effect-site concentrations of propofol that
are lower than in patients who undergo ACPS.
 To examine how many times patients using PMPS
press their trigger button to increment their dose
(successful button press), how many times they
press the button while the device is locked out
(unsuccessful button press) and whether there is a
relationship between pre-operative anxiety state and
use of the trigger system.
 To determine whether patients undergoing PMPS
experience a different incidence of airway, respiratory
or cardiovascular sedation-related side-effects than
patients who have undergone ACPS. Airway
sedation-related side-effects include partial or
complete airway obstruction that requires the usual
clinical anaesthetist to apply one of the following
interventions: chin-lift, jaw thrust, nasopharyngeal
airway insertion, oropharyngeal airway insertion,
laryngeal mask insertion or endotracheal tube
insertion. Respiratory sedation-related side-effects are
respiratory rate fewer than 8 breaths per minute or
arterial oxygen saturations less than 88% in patients
with chronic obstructive pulmonary disease (COPD)
or 94% in all other patients. Cardiovascular
sedation-related side-effects include heart rate or
blood pressure reduction greater than 20% from
baseline, but such events may be related to spinal
anaesthesia rather than the sedation. All such events
will be noted by a study investigator and reviewed to
determine the likely aetiology. There are no objective
clinical criteria to determine this, but routine clinical
practice is to assimilate the presented information to
estimate the likely contribution from sedation, spinal
anaesthesia and/or another cause.
 To determine whether patients undergoing
PMPS experience different health-related
quality of life outcomes compared to patients
undergoing ACPS.
Study design and setting
The trial is an open-label, randomised, controlled
superiority trial recruiting adults who are undergoing
elective primary lower-limb arthroplasty with sedation
by propofol infusion by effect-site targeting into two
equal-sized parallel arms: PMPS and ACPS. The study
will be run as a single-centre study at Nottingham
University Hospitals National Health Service (NHS)
Trust. The trial will be conducted only in a secondary
care setting.
Trial intervention
Propofol 1% is licensed in the UK for “Sedation for
diagnostic and surgical procedures, alone or in combin-
ation with local or regional anaesthesia in adults and
children > 1 month” [14]. The trial will be using propo-
fol within the terms of this license. Patients randomised
to PMPS will receive propofol according to the following
algorithm: the effect-site target concentration of propo-
fol will be commenced at 0.5 μg.mL− 1 and increased by
0.2 μg.mL− 1 (when the patient presses the button) to a
maximum of 2.0 μg.mL− 1. Following a successful button-
induced increase in the effect-site target, further button
presses will not increase the target concentration for 2min
(this is termed the lockout period). If patients do not press
the button for 15min, the effect-site target will reduce by
0.1 μg.mL− 1, and will continue to reduce by 0.1 μg.mL− 1
every 15min to a minimum of 0.5 μg.mL− 1 in the absence
of a button-press. Patients randomised to ACPS will receive
propofol according to the following algorithm: the
effect-site concentration will be commenced at a level
determined by the supervising clinical anaesthetist and
incremented and decremented by them as they see fit. No
maximum or baseline levels will be pre-specified. This con-
stitutes standard clinical practice. Both groups will use
Schnider effect-site TCI modelling.
Safety
All pre-existing medication taken by a participant as part
of their usual medical care will be permitted.
Co-administration of sedatives, hypnotics or analgesics
during placement of spinal anaesthesia or during the
intra-operative sedation regime at the discretion of the
supervising clinical anaesthetist will be recorded. Behav-
ioural disinhibition is a well-recognised side-effect of
propofol sedation. This occurs regardless of whether the
propofol is delivered by intermittent bolus, fixed rate in-
fusion or target-controlled infusion. It manifests as pa-
tient movement (usually of the upper limbs) and/or
talking. It does not always respond readily to simple ver-
bal command from the supervising clinician to desist.
The standard treatment for this is for the supervising
clinical anaesthetist to actively alter the depth of
sedation at their discretion by either lightening or
deepening the degree of sedation according to clinical
circumstances and their professional judgement. In
either arm of the trial, if a patient displays disinhibited
behaviour that is disruptive to surgery or potentially
dangerous for the patient (for example, risking pulling
out their intravenous cannula), the supervising clinical
anaesthetist will be free to alter the patient’s depth of
sedation either by lightening or deepening sedation,
using a sedative agent of their discretion. This will be
recorded. No medications will be specifically prohibited
in this trial.
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In order to detect physiological changes that may
suggest unsafe sedation, both trial arms will have heart
rate, respiratory rate, arterial oxygen saturations, blood
pressure and depth of sedation measured and recorded
at 5 min intervals throughout the sedation period.
Adverse events, adverse device events, serious adverse
events and serious adverse device events will be recorded
and reported to the relevant bodies (trial Sponsor, device
manufacturer, Research Ethics Committee, Medicine and
Healthcare products Regulatory Agency).
Inclusion criteria
The inclusion criteria are as follows:
 Listed to undergo elective primary hip or knee
arthroplasty under spinal anaesthesia
 Expressing a pre-operative preference for sedation
during surgery
 Able to communicate in written and spoken English
 Capable of giving informed consent
 Age > 18 years
Exclusion criteria
 Allergy to propofol
 Male patients with body mass index (BMI) > 42 and
female patients with BMI > 37
 Medical contraindication to spinal anaesthesia (for
example local infection at injection site, patient
refusal, allergy to local anaesthetic agent, untreated
systemic infection or untreated coagulopathy)
 Expressing pre-operative preference for surgery to
be performed awake or under general anaesthesia
 Inability to use handheld trigger system of the
patient-maintained propofol sedation device (PMPSD)
 Pregnancy or breastfeeding
BMI is included as an exclusion criterion since in the
Schnider TCI model, lean body mass (LBM) is calculated
using the James formula. This has been shown to esti-
mate LBM satisfactorily in normal-weight and moder-
ately obese patients, but paradoxically in male patients
with BMI > 42 and female patients with BMI > 37 [15].
As a safety precaution to prevent inaccurate propofol
dosing in these groups we have excluded patients with
BMI above these thresholds.
Enrolment
Patient screening for eligibility and recruitment will be
conducted at the Theatre admission lounge, Nottingham
City Hospital campus. This site is where our patients are
usually treated. Screening will be performed by the
supervising clinical anaesthetist during their routine
pre-operative patient assessment. The supervising
clinical anaesthetist will notify a study investigator of po-
tentially eligible patients. The recruited patient will sign
and date the approved version of the informed consent
form before any procedures specific to the clinical inves-
tigation are performed.
The participant’s research data will be gathered during
a single visit to hospital, which forms part of usual clin-
ical care. A telephone consultation between a study
investigator and each participant will be performed at
post-operative day 7–10.
After enrolment, the participant will be given a
group-specific laminated educational leaflet explaining
their sedation system. Those allocated to PMPS will receive
written instructions on the use of the PMPSD and those al-
located to ACPS will receive written explanation on how
their supervising clinical anaesthetist will sedate them.
A pre-operative questionnaire will be administered to
all participants before they are taken to the anaesthetic
room. The following data will be recorded: age, gender,
whether hip or knee arthroplasty, surgeon initials, super-
vising clinical anaesthetist initials, patient weight and
height, American Society of Anaesthetist Physical Status
Classification, respiratory rate, arterial oxygen saturations,
heart rate, blood pressure (systolic, diastolic, mean) and
sedation score on the Modified Observer’s Assessment of
Alertness/Sedation (mOAA/S) Scale.
Intervention
The usual clinical care of non-invasive physiological moni-
toring will be established by the supervising clinical anaes-
thetist. They will insert an intravenous cannula and spinal
anaesthesia will be performed. When satisfied that adequate
spinal anaesthesia has been accomplished, they will com-
mence the participant on their allocated sedation regime.
Participants allocated to PMPS will have their sedation
infusion commenced at the minimum level of 0.5 μg.mL− 1
and will be given the handheld trigger button to press.
They will be told “Press the button if you want to be more
sleepy”. Participants allocated to ACPS will be com-
menced on an effect-site-steered TCI propofol infusion.
The supervising clinical anaesthetist will control the
effect-site target at their discretion.
Both sedation regimes will commence in the anaes-
thetic room, prior to the participant moving to theatre.
A study investigator will record physiological and sed-
ation outcome measures at 5-min intervals throughout
the sedation period.
The sedation regime will be discontinued at the end of
surgery when skin clips are applied to the wound. This
time will be noted by a study investigator. In the PMPS
group the handheld button will be withdrawn from the
patient and the TCI infusion stopped. In the ACPS
group the TCI infusion will be stopped. If, for any rea-
son, the sedation is discontinued prior to end of surgery,
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the reason will be noted in a free-text narrative response
by a study investigator.
Post-operative period
Participants will be transferred to the PACU where a study
investigator will continue physiological and sedation out-
come measures until readiness for discharge from PACU
is achieved. The modified Aldrete score will be recorded
at 5-min intervals from the time the sedation regime stops
until the time at which the participant is scored in excess
of 9, indicating readiness for safe discharge from PACU.
Once participants are ready for discharge from PACU a
study investigator will administer a short, group-specific
post-operative questionnaire including questions on psy-
chological variables (e.g. anxiety).
On post-operative day 7–10 (the exact timing depend-
ing on the availability and convenience of the partici-
pant), a study investigator will contact all patients by
telephone to conduct a group-specific post-operative
telephone questionnaire (including questions on anxiety
since the operation and the sedation experience) and a
brief structured interview (in order for us to gain more
in-depth data on the experience and perceptions of the
sedation experience for patients in the PMPS group).
The interview will include qualitative responses in order
to allow the participant to provide additional informa-
tion beyond that covered in the questionnaires.
On completion of the post-operative telephone ques-
tionnaire the participant’s enrolment in the trial will
cease. A SPIRIT schedule of trial enrolment, intervention
and assessment is shown in Fig. 1.
Statistical methods
Propofol consumption (milligrams) will be calculated in
participants randomised to the two study groups. Body
weight (kilograms) and height (centimetres) recorded at
the pre-operative assessment will be used. Length of
sedation is defined as the time from when the propofol
sedation is commenced by the supervising clinical anaes-
thetist up until the time when the first skin clip is
inserted to close the wound (at which point the anaes-
thetist will stop the sedation).
The alternative hypothesis is two-sided. The level of stat-
istical significance is 5%. The clinical superiority of PMPS
over ACPS will be shown if the mean rate is reduced by
29% (or more) when using PMPS, compared with ACPS.
The randomisation schedule will be computer-generated
using an 8-block design, with allocation advised by opaque
sealed envelope. The expected recruitment rate into the
study is 2 patients per week.
Sample size calculation
Our calculation is based on results from a pilot PMPS
study (n = 26) and prospectively gathered standard care
ACPS (n = 17), showing that the mean body-weight-nor-
malised rate of propofol consumption in the PMPS and
ACPS groups was 1.580 (SD = 0.755) and 2.231 (SD =
0.915), respectively. For power of 90% and level of signifi-
cance of 5% against the two-sided alternative hypothesis,
72 participants are required to detect the observed differ-
ence in mean rate using Welch’s two-sample t test.
Expecting 10% drop-out of participants, a sample size
of 80 is required. Participants who drop out from the
trial prior to randomisation will be removed from the
study and any trial data that may have been collected
on them or from them will be destroyed. All
participants dropping out after randomisation will be
included in the study by intention to treat and all
trial data collected up to the moment of drop out will
be retained for analysis.
Randomisation
Enrolled participants will be randomised by block ran-
domisation technique. An opaque sealed envelope ran-
domisation system will be used. Allocation concealment
will be achieved by the generation of an unpredictable al-
location sequence into sealed envelopes by an independ-
ent party, which will not be opened until patient consent
for inclusion has been obtained. This will be accessed by a
study investigator for the purposes of allocation. Random-
isation will be conducted on the day of surgery.
Statistical plan
All data collected will be summarised for reporting pur-
poses using descriptive statistics. The hypothesis test as-
sociated with the primary outcome will compare the two
mean consumption rates using standard statistical tests
chosen appropriate to underlying assumptions (e.g.
two-sample t test and the Wilcoxon-Mann-Whitney
test). Testing will be performed using datasets formed
according to inclusions based on intention to treat.
P values will be reported, with values less than 5%
declared statistically significant.
We will report analyses of secondary outcomes for
complete cases that contain no major clinical investiga-
tion plan violations. Amongst these, button-press data
will be modelled using count data regression methods,
with extension to bivariate models to distinguish be-
tween successful presses and unsuccessful presses. The
panel time-series of propofol consumption rates col-
lected throughout the sedation period alongside button
presses will together be modelled using marked-point
process methods. Ordinal responses recorded on a
Likert scale (peri-operative anxiety, patient satisfaction)
will be compared across trial arms using parametric
methods suitable to underlying assumptions and
non-parametric methods, such as the Wilcoxon rank
sum test. Preoperative and post-operative quality of
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recovery total scores will be compared using the
Wilcoxon matched pairs test. Inter-item correlations will
be computed and associations between scored items will
be compared using Spearman rank correlation. The Bon-
ferroni correction to allow for multiple comparisons will
be applied. Qualitative data obtained from structured
questions will be coded and computer-analysed. Any
missing outcome data will be imputed using either a
last-observation-carried-forward rule or, for the subset
of comparable secondary outcomes, use data routinely
measured and recorded as part of usual clinical care.
Health economic analysis aims to establish the net mon-
etary benefit due to the NHS from introducing PMPS
compared to the current practice of ACPS. Economic
modelling will rely on parameterisations developed from
the data gathered from all trial outcome measures, includ-
ing health-related quality of life from the Euroqol
(EQ)-5D-5 L questionnaire before/after data. These data
will be collected as part of the pre-operative and
post-operative participant interviews. Cost differentials
across the two trial arms are expected due to propofol use
and time to fitness for discharge from PACU.
No interim analyses are planned for this study. Any
deviation from the original statistical plan will be de-
scribed and justified in the final report.
Discussion
Trial blinding
Trial participants cannot usefully be blinded to their
intervention, since one group (PMPS) will be asked to
use an additional medical device (a trigger button)
whereas the other group (ACPS) will not. Some previous
trials have attempted to achieve participant blinding in
trials of patient-maintained sedation, by giving the con-
trol group (ACPS) a sham button to press. This blinding
technique has the potential to affect outcome measures
in the ACPS group thus we will not be using this blind-
ing technique. Some of the potential psychological bene-
fit of patient-maintained sedation is that patients are
able to exert control over their care. By giving patients
STUDY PERIOD
Enrolment Allocation Post-allocation
TIMEPOINT Day of surgery
Day of 
surgery
Pre-
operative 
(THAL)
Immediate 
Post-
operative 
(PACU)
Late post-
operative 
(by 
telephone)
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
PMPS X
ACPS X
ASSESSMENTS:
Demographics
X
Anxiety state
X X X
Health function and quality 
of life
X X
Satisfaction
X X
Sedation consumption
X
Readiness for discharge 
from theatre suite
X
Adverse event monitoring
Fig. 1 SPIRIT: Schedule of enrolment, intervention and assessments. THAL, Theatre admission lounge; PACU, Postoperative care unit; PMPS,
patient-maintained propofol sedation; ACPS, anaesthetist-controlled propofol sedation)
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in the control arm (ACPS) a button to press, this could
alter their psychological response to surgery and sed-
ation and provide additional anxiolysis and comfort, or
possibly the reverse. Additionally, the action of giving a
sham button to patients in the ACPS group, means they
are no longer receiving what would be considered nor-
mal anaesthetist-controlled propofol sedation.
The participant’s usual clinical team (anaesthetist, sur-
geon, operating department staff ) will not be blinded to
the intervention and will be independent from the trial
team. The supervising clinical anaesthetist will, for the
reasons outlined above, be impossible to blind, since
they will be delivering sedation directly to participants
allocated to the ACPS group. A blinding technique
giving both group participants a trigger button (a sham
one in the ACPS group) and both group participants an
ACPS infusion device (a sham one in the PMPS group)
would be very difficult logistically in a theatre environ-
ment, be unlikely to provide effective blinding, would
alter the psychological responses to surgery and sedation
in both groups reducing the validity of comparison be-
tween groups and provide little benefit when it comes to
assessing and reducing bias in the outcome measures we
are proposing.
The study investigator who is allocated to collect
intra-operative data will not be blinded to the allocation
groups. Recording of physiological data will be taken
from the usual intra-operative monitoring system in
place in theatre, which is in close physical proximity to
the participant and their infusion devices. It would not
be realistic to blind the observer to this monitoring.
Trial status
This protocol is version number 2.0 dated 2 August
2018. Recruitment is planned to commence on 18
September 2018 and be completed by 1 February 2020.
The trial Sponsor is Nottingham University Hospitals
NHS Trust (researchsponsor@nuh.nhs.uk).
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents*. (DOC 121 kb)
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